Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
FINANCIAL Report:
Zacks Equity Research, On Thursday October 28, 2010, 3:35 pm EDT
California-based genetic products maker Affymetrix Inc. (NasdaqGS: AFFX - News) reported third-quarter fiscal 2010 adjusted net loss per share of 4 cents, lower than the Zacks Consensus Estimate of a loss of 6 cents. The adjusted loss excludes one-time items including a $4.1 million gain on repurchase of convertible notes.
Affymetrix posted a net income (on a reported basis) of $1 million (or 1 cent a share) as against a net loss of $8.8 million (or 13 cents a share) in the year-ago quarter. Besides the above-mentioned gain, the turnaround is attributable to the company’s cost management initiatives, which offset lower sales.
Revenue Analysis
Revenueswereclipped 5.4% year-over-year to $74 million, yet modestly beating the Zacks Consensus Estimate of $73 million. Sales were affected by lower revenues from the company’s scientific services.
Product revenues rose 1.7% year-over-year to $67.3 million. Instrument revenues climbed 28.6% year-over-year to of $5.4 million. DNA and RNA products sales declined 1% and 6%, respectively. Service revenues slid 50% to $4.9 million, affected by the completion of several large genotyping projects.
A still-soft operating backdrop in Europe is affecting Affymetrix, although, to a lesser extent compared to the previous quarter. The company’s European business has been hurt by lower spending by academic research organizations, impacted by government actions (such as budget cuts) to address surging debt levels and weak currencies.
Margins
Gross margin rose to 55% from 54% a year-ago, helped by effective cost-cutting efforts. Product gross margin increased to 56% from 54% driven by higher margins for the company’s array products. Consolidated costs and expenses fell roughly 11% year-over-year to $76 million.
Financial Condition
Affymetrix exited the quarter with cash and cash equivalents of $40.1 million, down 36% year-over-year. The company de-leveraged its balance sheet in the quarter having bought back roughly $71.9 million of its 3.5% convertible notes, which trimmed the outstanding convertible debt balance to $148.6 million from $220.5 million in the previous quarter.
Outlook
Affymetrix has not divulged any updated outlook for the remainder of 2010. However, the company expects to be cash flow positive through 2010.
Affymetrix is a leading provider of microarray-based products and services to the global research community. It is one of the two major providers - along with Illumina Inc. (NasdaqGS: ILMN - News) - of microarray technologies. The company is broadening its customer base through new product introductions and strategic alliances. However, itis increasingly being challenged by competitive product offerings that leverage advanced technologies.
Affymetrix continues to enjoy steady end-user demand for its arrays as evidenced by sustained volume growth over the past few quarters. The company’s Axiom array platform (launched in October 2009) has been a key driver for its DNA business.
To broaden its Axiom platform, Affymetrix launched the Axiom Custom Genotyping Arrays in July 2010. This new solution enables the company to address the latest trends in genetic research.
Zacks Investment Research
Affymetrix Custom Arrays Enable Breakthrough Malaria Discoveries
Date : 10/22/2010 @ 4:42PM
Source : Business Wire
Stock : Affymetrix, Inc. (AFFX)
Quote : 4.55 0.03 (0.66%) @ 7:22AM
Affymetrix Custom Arrays Enable Breakthrough Malaria Discoveries
Affymetrix (NASDAQ:AFFX)
Intraday Stock Chart
Today : Friday 22 October 2010
Affymetrix, Inc. (NASDAQ: AFFX) announced today that an international team of researchers led by scientists at Boston College, the Broad Institute, and Imperial College London used an Affymetrix custom microarray to advance the study of malaria by assessing the variation in genetic structure and detecting known and novel genetic differences among malaria vector mosquito populations. This study will enable association studies that link mosquito genes to insecticide resistance and parasite infection susceptibility, ultimately helping to reduce malaria transmission.
Published today in the journal Science, this groundbreaking discovery by a global consortium of 17 scientists, will enable more research on effective interventions against malaria, which annually sickens more than 240 million people and causes 860,000 deaths, most among young children. While advances in insecticides and anti-malarials have reduced transmission and death rates, the rate of decline is in danger of slowing due to increasing resistance to interventions, the mosquito’s adaptive nature, and the pathogen’s ability to evade mosquito defenses.
“The renewed goal among malaria researchers, advocated by Melinda Gates of the Gates Foundation in 2007, is to eradicate malaria in our lifetime,” said lead researcher Marc Muskavitch, DeLuca Professor of Biology at Boston College. “But vaccines have not been successful, and insecticides and anti-malarials keep losing effectiveness. If we are going to eradicate it, new interventions are needed,” he added. “What we needed was a better tool to look at the complexity of mosquito populations, to help us find genes that help mosquitoes evade our interventions and transmit disease.”
The team used the Anopheles gambiae (AG) SNP1 Array, a proprietary microarray designed by Affymetrix in collaboration with the research team. The array features 400,000 SNPs of the 3 million found among four sequenced strains of Anopheles gambiae, providing vastly higher resolution than the 42- and 1,536-marker sets otherwise available to malaria vector biologists.
Over several malaria seasons, the international consortium, including scientists from the University of Notre Dame, the Malaria Research and Training Center in Mali, and the Harvard School of Public Health, collected mosquito samples from Mali and Burkina Faso and used the Affymetrix platform to genotype samples to validate array probes and define a vastly expanded SNP marker set for this malaria vector mosquito.
“With a higher resolution than ever before, we are beginning to understand how malaria vector mosquito populations become separated reproductively, in a process called ‘incipient speciation,’ and develop different traits to become better at evading interventions we deploy against them,” noted Muskavitch. “Now we are developing new collaborations to use this tool to understand the genes underlying resistance to insecticides and the ability of mosquitoes to transmit malaria. Understanding those genes can help us to control mosquito populations more effectively, and try to help the mosquito use its defenses more effectively to reduce malaria parasite transmission.”
“This groundbreaking research put scientists in the malaria community a step closer to identifying mosquito genes and alleles linked to malaria transmission, insecticide resistance, and parasite vulnerability,” said Affymetrix President and CEO Kevin King. “Thanks to their work, the prospect of significantly reducing the spread of this disease and improving the lives of millions of people around the globe is within reach.”
The scientists plan to encourage adoption of the AG SNP1 Array within the vector biology community in preparation for the next wave of research, which will focus on understanding the complexity of the mosquito populations in even greater depth, the mosquito genes that affect Plasmodium transmission, and the genes that can be used to improve mosquito control.
“We plan to make this powerful array available to the community,” said Muskavitch. “We’re expecting to complete this effort by early next year, when Affymetrix will make it available.”
“As part of our ongoing focus on enabling genomic research in a wide range of species and disease and infectious areas, we are pleased to partner with Drs. Muskavitch of Boston College, Roger Wiegand of the Broad Institute, and their entire team to make this valuable research tool broadly available to the scientific community,” said Jay Kaufman, Vice President of Strategic Marketing, DNA Applications, at Affymetrix. “With our long history of these partnerships, we recognize the value of cutting-edge scientific research combined with proven microarray technologies, and the overall benefit this brings to those pursuing the improvement of human health.”
Another Affymetrix custom array is helping scientists looking to develop more effective treatments for malaria. The GNF Malaria Tiling Array, a high density tiling array of Plasmodium falciparum, developed in collaboration with the Genomics Institute of the Novartis Research Foundation, was used by an international team of scientists responding to increased tolerance to a new class of anti-malarials. Led by genomic scientist Elizabeth Winzeler of the Department of Cell Biology at the Scripps Research Institute, the team used the array to screen a diverse chemical library for new parasite-killing compounds and discovered a parasite gene that mediates resistance to a new potential drug lead. "Affymetrix microarray technology allowed us to rapidly examine the entire genome of the resistant malaria parasite strains and discover newly evolved mutations in PfATP4 that may be involved in maintaining ion homeostasis,” said Winzeler. “Microarrays allowed us to simultaneously identify both the single-base changes and the copy number variants in PfATP4. It is not clear that we would have been as successful if we had used full-genome sequencing instead.”
Affymetrix scientists collaborate with the scientific community in the MyGeneChip™ Custom Array Service program to deliver consistent, reproducible results across all types of studies and are widely respected for ensuring excellence in research and development in probe selection, array design, and manufacturing.
About Affymetrix
Affymetrix technology is used by the world's top pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and nonprofit research institutes. More than 1,900 systems have been shipped around the world and more than 22,000 peer-reviewed papers have been published using the technology.
Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Cleveland, Ohio, and Singapore. The company has about 1,000 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit www.affymetrix.com.
Forward-looking statements
All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies," or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected. These and other risk factors are discussed in Affymetrix' Form 10-K for the year ended December 31, 2009, and other SEC reports for subsequent quarterly periods.
NOTE: Affymetrix, the Affymetrix logo, and GeneChip are trademarks or registered trademarks of Affymetrix, Inc.
AFFX- Above 52 weeks' low of 3.75 and below its $8.00 high . $4.75 again! Very similar trends to AFFY!
Affymetrix to Webcast Presentations at September Financial Conferences
Date : 09/09/2010 @ 6:00AM
Source : Business Wire
Stock : Affymetrix, Inc. (AFFX)
Quote : 4.64 0.21 (4.74%) @ 7:22AM
Affymetrix to Webcast Presentations at September Financial Conferences
Affymetrix (NASDAQ:AFFX)
Intraday Stock Chart
Today : Friday 10 September 2010
Affymetrix, Inc. (Nasdaq:AFFX) today announced that company management will provide a corporate overview at four financial conferences in September.
Morgan Stanley Healthcare Conference, New York, NY on Mon. Sept. 13th at 1:00pm ET
R.W. Baird Healthcare Conference, New York, NY on Weds. Sept. 15th at 1:15pm ET
Stifel Nicolaus 2010 Healthcare Conference, Boston, MA on Fri. Sept. 17th at 9:45am ET
UBS Global Life Sciences Conference, New York, NY on Weds. Sept. 22nd at 1:00pm ET
Live webcasts of all presentations will be available at http://www.affymetrix.com under the "Investors" link. Archived webcasts will be available for 30 days.
About Affymetrix
Affymetrix technology is used by the world's top pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and nonprofit research institutes. More than 1,900 systems have been shipped around the world and more than 22,000 peer-reviewed papers have been published using the technology.
Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Cleveland, Ohio, and Singapore. The company has about 1,000 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit http://www.affymetrix.com.
NOTE: Affymetrix, the Affymetrix logo and GeneChip(R) are registered trademarks owned or used by Affymetrix Inc.
"Margins' performance @AFFX"
http://www.fool.com/investing/general/2010/08/11/marginal-performance-at-affymetrix.aspx?source=idesitit10000001
Surf; Which fifty stocks you dropped?
tia
mlkr
Affymetrix to Commercialize Powerful Genotyping Array for Chinese Population
Date : 07/27/2010 @ 9:00AM
Source : Business Wire
Stock : Affymetrix, Inc. (AFFX)
Quote : 4.59 -0.08 (-1.71%) @ 7:22AM
Affymetrix to Commercialize Powerful Genotyping Array for Chinese Population
Affymetrix (NASDAQ:AFFX)
Intraday Stock Chart
Today : Tuesday 27 July 2010
Affymetrix, Inc. (NASDAQ:AFFX) today announced that it will develop and commercialize the Axiom™ Chinese myDesign™ Genotyping Array, the first product that provides maximum power for genome-wide association studies (GWAS) specifically on Chinese populations.
“Working with our customers in China to design this array, and establishing a fully legal entity in China, further demonstrates our commitment to broadening our capabilities and technical support specifically in China,” said William Cao, Affymetrix General Manager of China Operations. “We look forward to continuing our work with the leading genomic researchers in China to strengthen our ability to bring effective technologies to market.”
The new Chinese myDesign Genotyping Array is part of a suite of population-optimized arrays to be released this year that leverage the Affymetrix Axiom Genomic Database, the world’s largest collection of validated common and rare SNPs for creating custom arrays containing 50,000 to as many as 2.6 million SNPs. In addition to GWAS, this inherent flexibility allows researchers to conduct population-specific replication, fine mapping, and candidate gene studies on a single platform. Scientists focusing on the Chinese population will now be able to generate meaningful data with the most relevant SNPs for their cohort.
“Affymetrix’ ability to use their database of validated SNPs to select markers that are most relevant in the Chinese population will result in an array that will give me the highest genomic coverage,” said Dr. Lin He, a leading genomic researcher at Shanghai Jiao Tong and Fudan Universities and a member of the Chinese Academy of Sciences. “This will significantly increase the likelihood of finding successful associations in my schizophrenia research and in the hypertension project led by my colleague, Dr. Dong Feng Gu of Beijing Fuwai Hospital.” Both projects are funded by China’s Ministry of Science and Technology.
The Chinese myDesign Genotyping Array will enable researchers to characterize the genetic basis of disease in Chinese populations and leverage high genomic coverage from other Asian populations, making it a powerful, high-throughput tool for human disease research. The Chinese myDesign Genotyping Array features optimized genomic coverage leveraging common variants from a validated set of markers shown to be polymorphic in Chinese samples.
"Expanding our Axiom family of genotyping products to cover the Chinese population comes in response to Dr. He’s scientific insights on genotyping study design,” said Jay Kaufman, Vice President of DNA Product Marketing at Affymetrix. "Our customers in China, including Dr. He and Dr. Yong Yong Shi, who run the largest genotyping lab in China, called for more focused, Chinese-specific content to give them greater genetic coverage and thus more power. The Chinese myDesign Genotyping Array meets these needs.”
The array is in development and will be commercialized later this year for other researchers interested in leveraging this powerful research tool.
"Affymetrix customers are at the forefront in an ever-changing field of genotyping studies, and it is our mission to continue providing the genetic data and microarray technology that will keep them at the cutting edge of human disease research,” said Affymetrix President and CEO Kevin King. "Dr. He’s Bio-X Center at Shanghai Jiao Tong University has been an Affymetrix Model Lab since 2008 and now, with more robust Chinese-specific content on our Axiom Custom Genotyping Array platform, his research team will gain an even better understanding of the role that genes play in disease, the effectiveness and safety of therapies, and many other biological factors that affect well-being in the Chinese population."
The Axiom platform’s groundbreaking customization capabilities allow researchers to combine SNPs from their own sequencing projects and other sources with Affymetrix' validated SNPs to design their own arrays with up to 2.6 million SNPs. In the near future, this capability will expand to support custom array designs containing more than 5 million SNPs. Content for the Chinese myDesign Genotyping Array was drawn from the 1000 Genomes Project as well as Han Chinese data made available through the International HapMap Project.
To learn more about Axiom Custom Genotyping Arrays, please visit www.affymetrix.com/axiom.
About Affymetrix
Affymetrix technology is used by the world’s top pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and nonprofit research institutes. More than 1,900 systems have been shipped around the world and more than 21,000 peer-reviewed papers have been published using the technology.
Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Cleveland, Ohio, and Singapore. The company has about 1,000 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit www.affymetrix.com.
Forward-looking statements
All statements in this press release that are not historical are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix’ “expectations,” “beliefs,” “hopes,” “intentions,” “strategies,” or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected. These and other risk factors are discussed in Affymetrix’ Form 10-K for the year ended December 31, 2009, and other SEC reports for subsequent quarterly periods.
NOTE: Affymetrix, the Affymetrix logo, Axiom, and myDesign are trademarks or registered trademarks of Affymetrix, Inc.
Biotechs running out of cash are faced with either further diluting their shareholders (if they can find the investors to buy the shares), or making the tough decisions on pulling back from their trials--if they have a few going at the same time--to conserve that cash.
And those biotechs that have only one drug candidate.Well, need I say more?
Affymetrix Announces Preliminary Revenue for Second Quarter 2010
Date : 07/07/2010 @ 8:23AM
Source : Business Wire
Stock : Affymetrix, Inc. (AFFX)
Quote : 4.3 -1.25 (-22.52%) @ 7:22AM
Affymetrix Announces Preliminary Revenue for Second Quarter 2010
Affymetrix (NASDAQ:AFFX)
Intraday Stock Chart
Today : Wednesday 7 July 2010
Affymetrix, Inc. (Nasdaq:AFFX) today reported that based on preliminary financial data, the Company expects total revenue for the second quarter of 2010 to be in the range of $71-72 million, as compared to the Company’s previous guidance in the range of $80-82 million. The company expects product revenue for the second quarter of 2010 to be approximately $65-66 million, including instrument sales of approximately $4-5 million and consumable sales of approximately $60-61 million.
The principal factors that contributed to the lower than expected second quarter revenue include:
Delayed and lengthened capital equipment purchase cycles by academic research customers, particularly in Europe;
Increased sales of DNA products offset by declines in RNA sales that were related to the integration of recent acquisitions and the realignment of sales territories; as well as
Material deterioration in both the Euro and British Pound of $1 million in aggregate since the Company provided second quarter guidance on April 21, 2010.
“When the Company previously issued guidance for the second quarter of 2010, we anticipated that growth in product sales would offset an expected decline in services revenue as compared to the second quarter of 2009,” stated Kevin M. King, president and CEO. “However, instrument adoption was slower than anticipated, principally due to reduced foreign academic research spending. In Europe, we believe our business was impacted by governmental actions taken to address high levels of debt and weakening currencies.”
“Despite the challenges we experienced in the second quarter, we are confident our business is moving in the right direction and we are focused on growing the business beyond the basic research market,” continued King.
Tim Barabe, executive vice president and CFO, said, “We continue to make good progress in reducing our operating expenses and we expect to be cash-flow positive on an operating basis in each quarter of fiscal year 2010. In addition, we have a strong balance sheet and expect to report about $100 million in net cash as of June 30, 2010.”
The Company noted that it will not be providing updated revenue guidance for the remainder of 2010 due to uncertainty regarding academic research funding and foreign currency fluctuations.
The Company will provide further information when it reports second quarter 2010 results after the close of the market on Wednesday, July 21, 2010. Affymetrix’s management team will host a conference call on July 21, 2010 at 2:00 p.m. PT. A live webcast can be accessed by visiting the Investor Relations section of the Company's website at http://www.affymetrix.com. In addition, investors and other interested parties can listen by dialing domestic: (866) 500-AFFX, international: (706) 645-9291. The passcode for both replays is 85766840.
About Affymetrix
Affymetrix GeneChip® microarray technology is the industry-standard tool for analyzing complex genetic information. After inventing microarray technology in the late 1980s, Affymetrix scientists have been dedicated to developing innovative products that provide researchers with a more complete view of the genome. These products continue to accelerate genetic research and enable scientists to develop diagnostics and tailor treatments for individual patients by identifying and measuring the genetic information associated with complex diseases.
Today, Affymetrix technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies, as well as leading academic, government and not-for-profit research institutes. More than 1,950 systems have been shipped around the world and more than 21,000 peer-reviewed papers have been published using the technology.
Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Cleveland, Ohio, and Singapore. The company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit: www.affymetrix.com.
Affymetrix has not filed the Form 10-Q for the second quarter of fiscal 2010. As a result, all financial results described in this press release should be considered preliminary, and are subject to change to reflect any necessary corrections or adjustments, or changes in accounting estimates, that are identified prior to the time the company is in a position to complete these filings.
All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies" or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to: risks related to the adoption of our new products, risks related to past and future acquisitions; risks of the company's ability to achieve and sustain higher levels of revenue, higher gross margins and reduced operating expenses; uncertainties relating to technological approaches, manufacturing and product development; risks that the actual results for the second quarter of 2010 will vary from the preliminary estimates reflected in this release; risks of personnel retention; uncertainties related to cost and pricing of Affymetrix products; dependence on collaborative partners; uncertainties relating to sole-source suppliers; uncertainties relating to FDA and other regulatory approvals; competition; risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix' Form 10-K for the year ended December 31, 2009, and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
AFFX has net cash of only about $40m as of 3/31/10
$300m cash + st inv
$43m long term inv (longer dated securities - treat as near cash)
$60m st liabilities
$250m debt
so lets say $350m liquid assets and about $310m liaiblities/debt
net "cash" about $40m +/- or a bit less then $.60 a share.
AFFX has net cash of only about $40m as of 3/31/10
$300m cash + st inv
$43m long term inv (longer dated securities - treat as near cash)
$60m st liabilities
$250m debt
so lets say $350m liquid assets and about $310m liaiblities/debt
net "cash" about $40m +/- or a bit less then $.60 a share.
AFFX $4.00s now! 8:26AM Affymetrix lowers Q2 rev guidance below consensus (AFFX) 5.55 : Co issues downside guidance for Q2 (Jun), sees Q2 (Jun) revs of $71-72 mln, down from $80-82 mln previously and the $82.15 mln Thomson Reuters consensus. Co cites delayed and lengthened capital equipment purchase cycles by academic research customers, particularly in Europe; "instrument adoption was slower than anticipated, principally due to reduced foreign academic research spending. In Europe, we believe our business was impacted by governmental actions taken to address high levels of debt and weakening currencies."
Dropping AFFX this morning, the stock like many other biotech stocks will continue to be under pressure in the coming months. The debt load on this company will keep it down longer when others start to bottom toward the end of the year. I have now dropped about 50 biotech MOD positions in the past couple of months. Most of these stocks should just be watched for now...
surf
Total Cash (mrq): 301.36M
Total Cash Per Share (mrq): 4.25
Total Debt (mrq): 247.20M
Total Debt/Equity (mrq): N/A
Current Ratio (mrq): 7.08
Book Value Per Share (mrq): 4.07
Affymetrix cuts 2Q revenue guidance
Affymetrix cuts 2nd-quarter revenue guidance on delayed purchases, weaker euro
http://finance.yahoo.com/news/Affymetrix-cuts-2Q-revenue-apf-144116721.html?x=0&.v=1
Signature Diagnostics to Use Affymetrix Microarray Technology for Advanced Colorectal Cancer Tests
Date : 06/28/2010 @ 9:00AM
Source : Business Wire
Stock : Affymetrix, Inc. (AFFX)
Quote : 6.35 -0.05 (-0.78%) @ 7:22AM
Signature Diagnostics to Use Affymetrix Microarray Technology for Advanced Colorectal Cancer Tests
Affymetrix (NASDAQ:AFFX)
Intraday Stock Chart
Today : Monday 28 June 2010
Click Here for more Affymetrix Charts.
Affymetrix, Inc. (NASDAQ:AFFX) and Signature Diagnostics AG (Signature Dx) today announced that they have signed a Powered by Affymetrix™ (PbA) agreement.
Affymetrix to Webcast Presentation from Jefferies 2010 Global Life Sciences Conference
Date : 06/03/2010 @ 4:54PM
Source : Business Wire
Stock : Affymetrix, Inc. (AFFX)
Quote : 6.73 0.12 (1.82%) @ 7:22AM
Affymetrix to Webcast Presentation from Jefferies 2010 Global Life Sciences Conference
Affymetrix, Inc. (NASDAQ: AFFX) today announced the webcast of its presentation at the Jefferies 2010 Global Life Sciences Conference in New York City.
Doug Farrell, Vice President of Investor Relations and Treasury, will present on Friday June 11th at 9:00a ET. To hear a live webcast of the presentation, visit the investor relations page on the Company's Web site at www.affymetrix.com. An archived webcast will be available for 30 days.
About Affymetrix
Affymetrix technology is used by the world’s top pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and nonprofit research institutes. More than 1,900 systems have been shipped around the world and more than 21,000 peer-reviewed papers have been published using the technology.
Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Cleveland, Ohio, and Singapore. The company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit www.affymetrix.com.
Affymetrix Delivers First Custom Axiom Array for Kaiser Permanente/UCSF Genotyping Project
Date : 05/10/2010 @ 9:00AM
Source : Business Wire
Stock : Affymetrix, Inc. (AFFX)
Quote : 6.69 0.56 (9.14%) @ 9:01AM
Affymetrix Delivers First Custom Axiom Array for Kaiser Permanente/UCSF Genotyping Project
Affymetrix, Inc. (NASDAQ: AFFX) today announced that it has delivered the first custom array designed for a 100,000-sample genotyping project to be performed using the Axiom™ Genotyping Solution. The array, optimized for European populations, was developed in conjunction with researchers from the Kaiser Permanente Division of Research and University of California, San Francisco (UCSF) as part of an NIH-funded project to create a new resource for studying disease, health, and aging.
The custom array will be used to genotype a significant portion of 100,000 samples collected by the Kaiser Permanente Research Program on Genes, Environment, and Health (RPGEH), which aims to enroll and collect DNA samples for research from 500,000 Kaiser Permanente members in Northern California by 2013.
The array leverages the Axiom database of approximately 6 million validated SNPs and demonstrates their extremely high conversion rate. With content from more than 30 sources, including the 1000 Genomes Project, the array has excellent genetic coverage of low-frequency SNPs relative to other commercially available genome-wide genotyping arrays. Affymetrix will make this array available to any researcher.
Based on initial quality control results, the array’s performance exceeds typical genotyping performance metrics with call rates greater than 99.6 percent and HapMap concordance in excess of 99.7 percent.
To prepare for the large genotyping project, the UCSF/Kaiser Permanente team has completed two pilot projects comprising more than 6,000 samples using the Axiom Genome-Wide Human Array Plate, the CEU-optimized catalog array launched in October 2009.
“This project will generate unprecedented data that will provide the basis for many new studies in the areas of disease outcomes, response to treatment, and factors influencing healthy aging and longevity,” said Cathy Schaefer, PhD, Executive Director of the Kaiser Permanente RPGEH. “We are grateful to Kaiser Permanente members, whose participation in the research program makes this genotyping project possible.”
The complete Axiom Genotyping Solution consists of Axiom Array Plates, complete Axiom Reagent Kits, an automated target preparation protocol developed jointly by Affymetrix and Beckman Coulter, and the GeneTitan® Instrument. Scientists can run more than 760 samples per week with considerably less user intervention relative to competing products.
“Our collaboration with the Kaiser Permanente/UCSF teams has resulted in these milestones, which demonstrate the overall power of the Axiom Genotyping Solution and our database of validated SNPs,” said Kevin King, President and CEO of Affymetrix. “This approach not only leverages Affymetrix’ expanding capabilities in custom genotyping arrays, but also illustrates the need for flexibility and the desire to precisely tailor custom arrays.”
The Kaiser Permanente/UCSF genotyping project of 100,000 samples is made possible by a $24.8 million grant from the National Institutes of Health awarded jointly to the Kaiser Permanente Division of Research and the UCSF Institute for Human Genetics to create a new resource for studying disease, health, and aging.
About Affymetrix
Affymetrix technology is used by the world’s top pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and nonprofit research institutes. More than 1,900 systems have been shipped around the world and more than 21,000 peer-reviewed papers have been published using the technology.
Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Cleveland, Ohio, and Singapore. The company has about 1,000 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit www.affymetrix.com.
UCSF disclaimer
The information stated above was prepared by Affymetrix, Inc., to report status of a custom array and reflects solely the opinion of Affymetrix, Inc. Nothing in this statement shall be construed to imply any support or endorsement of Affymetrix, Inc., or any of its products, by The Regents of the University of California, its officers, agents and employees.
Forward-looking statements
All statements in this press release that are not historical are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix’ “expectations,” “beliefs,” “hopes,” “intentions,” “strategies,” or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected. These and other risk factors are discussed in Affymetrix’ Form 10-K for the year ended December 31, 2008, and other SEC reports for subsequent quarterly periods.
NOTE: Affymetrix, the Affymetrix logo, Axiom, and GeneTitan are trademarks or registered trademarks of Affymetrix Inc.
Beckman Coulter® and Biomek® are registered trademarks of Beckman Coulter, Inc. Beckman Coulter Biomek Systems are for Laboratory Use Only; not for use in diagnostic procedures.
Family Tree DNA Launches Family Finder DNA Test Using Affymetrix Microarray Technology
Date : 05/03/2010 @ 6:00AM
Source : Business Wire
Stock : Affymetrix (AFFX)
Quote : 6.95 -0.21 (-2.93%) @ 7:22AM
Family Tree DNA Launches Family Finder DNA Test Using Affymetrix Microarray Technology
Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix’ (NASDAQ:AFFX) recently launched Axiom™ genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.
Family Finder represents a major advancement over earlier genealogical tests, which revealed only connections along specific paternal lines (for males) or maternal lines (males or females). Family Finder enables anyone, regardless of gender, to look for connections such as grandparents, aunts and uncles, half siblings, and first, second, third, and fourth cousins.
“This is the most exciting genetic genealogy breakthrough since 2000, when Family Tree DNA launched its Y-DNA test to uncover relatives in the direct paternal line,” said Bennett Greenspan, founder and CEO of Family Tree DNA. “The comprehensive, genome-wide coverage of Axiom Arrays enables us to offer consumers the most advanced genealogical test available at a price that is attractive to our customers. In addition, the automated GeneTitan System allows us to process hundreds of samples at a time with minimal hands-on time for maximum efficiency.”
The Family Finder test analyzes the DNA of two individuals using Axiom Array Plates containing nearly 570,000 genetic markers, including many that are relevant to genealogy. Family Tree DNA then analyzes the resulting data with internally developed algorithms to determine the closeness of the relationship. The complete Axiom Genotyping Solution includes array plates, complete reagent kits, and an automated workflow that enables scientists to process more than 760 samples per week.
Family Tree DNA offers counseling services, tutorials, and other helpful tools to assist in the genealogy and matching process, and provides names and email addresses of matched individuals whenever possible for easy communication.
“The Family Finder test represents a huge step forward for the direct-to-consumer genetic genealogy market and the application of microarray technology,” said Kevin King, president and CEO of Affymetrix. “Now anyone can utilize the power of the Axiom Genotyping Solution and the GeneTitan System to find and connect with a broader range of family members than ever before.”
For more information about the Family Finder test, please visit www.familytreedna.com.
For more information about Affymetrix products for genetic research, please visit www.affymetrix.com.
About Family Tree DNA
Founded in April 2000, Family Tree DNA (www.familytreedna.com) was the first company to develop the commercial application of DNA testing for genealogical purposes, something that had previously been available only for academic and scientific research. Almost a decade later, the Houston, Texas-based company has a database with over 290,000 individual records – the largest DNA database in genetic genealogy, a number that makes Family Tree DNA the prime source for anyone researching recent and distant family ties. In 2006 Family Tree DNA established a state-of-the-art Genomics Research Center at its headquarters in Houston, where it currently performs R&D and processes over 200 advanced types of DNA tests for its customers, including the new Family Finder test.
About Affymetrix
Affymetrix technology is used by the world’s top pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and nonprofit research institutes. More than 1,900 systems have been shipped around the world and more than 21,000 peer-reviewed papers have been published using the technology.
Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Cleveland, Ohio, and Singapore. The company has about 1,000 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit www.affymetrix.com.
The Axiom Genotyping Solution and the GeneTitan Instrument are for research use only and are not for use in diagnostic procedures.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6273501&lang=en
Affymetrix Launches Axiom Genome-Wide ASI Array For Maximized Coverage of East Asian Populations
Date : 04/26/2010 @ 9:00AM
Source : Business Wire
Stock : Affymetrix, Inc. (AFFX)
Quote : 6.68 0.0 (0.00%) @ 7:22AM
Affymetrix Launches Axiom Genome-Wide ASI Array For Maximized Coverage of East Asian Populations
Affymetrix, Inc. (NASDAQ:AFFX) today announced the launch of the Axiom™ Genome-Wide ASI Array, the first commercial product to provide maximum power for genome-wide association studies (GWAS) in East Asian populations. This array is the second catalog release for the Axiom™ Genotyping Solution, which includes a suite of population-optimized arrays for genomic studies that will be delivered in the next year.
The Axiom Genome-Wide ASI Array enables researchers to characterize the genetic basis of disease in Asian populations and also offers high genomic coverage for Caucasian populations, making it a powerful, high-throughput tool for ancestry, population, and personal genomic studies.
“There is evidence that differences in disease frequencies and intensity within different populations may have a genetic basis,” said Dr. Edison Liu, Executive Director of the Genome Institute of Singapore (GIS), which is using the Axiom Genome-Wide ASI Array in ongoing studies to explore the genetic basis of disease in East Asian populations.
“The increase in knowledge of population-specific human genetic variation is paying off with the creation of GWAS arrays optimized for specific populations,” said Dr. Liu, adding that he is pleased with this advanced approach to genome-wide array design.
“This offers researchers increased power to detect population-specific allele associations. With the dramatically increased intensity of research in population genetics in Asia, the Axiom Genome-Wide ASI Array will offer tailored precision for the identification of disease alleles.”
The Genome-Wide ASI Array optimizes genomic coverage with known disease association markers, chromosomes X and Y, mitochondrial genomes, and ADME genes. Content was drawn from the 1000 Genomes Project as well as Han Chinese and Tokyo Japanese data made available through the International HapMap Project.
Dr. Jianjun Liu, Group Leader and Associate Director of the Human Genetics group at GIS, is pleased with the performance of the Axiom Genome-Wide ASI Array. “We have run more than 1,000 samples with average call rates above 99.7 percent and HapMap concordance in excess of 99.8 percent,” said Dr. Jiu.
The complete Axiom Genotyping Solution consists of Axiom ASI Array Plates, complete Axiom Reagent Kits, an automated target preparation station developed jointly by Affymetrix and Beckman Coulter, and the GeneTitan® Instrument. The GeneTitan Instrument integrates a hybridization oven, fluidics processing, CCD imaging device, and analysis software for maximum data reproducibility, user productivity, and scalability. Scientists can run more than 760 samples per week with minimal user intervention, a significant advantage over competing products.
“The ASI Array offers a complete solution to researchers looking for novel genetic variations associated with complex disease in East Asian populations,” said Kevin King, president and CEO. “This solution is ideally suited to customers interested in exploring the genetic complexities underlying disease in Asian populations. We look forward to further expanding the Axiom family of genotyping products in the future.”
For more information about Axiom Genotyping Solution, please visit www.affymetrix.com/axiom
Beckman Coulter® and Biomek® are registered trademarks of Beckman Coulter, Inc. Beckman Coulter Biomek Systems are for Laboratory Use Only; not for use in diagnostic procedures.
About Affymetrix
Affymetrix technology is used by the world’s top pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and nonprofit research institutes. More than 1,900 systems have been shipped around the world and more than 21,000 peer-reviewed papers have been published using the technology.
Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Cleveland, Ohio, and Singapore. The company has about 1,000 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit www.affymetrix.com.
About the Genome Institute of Singapore
The Genome Institute of Singapore (GIS) is a member of the Agency for Science, Technology and Research (A*STAR). It is a national initiative with a global vision that seeks to use genomic sciences to improve public health and public prosperity. Established in 2001 as a centre for genomic discovery, the GIS will pursue the integration of technology, genetics and biology towards the goal of individualized medicine. The key research areas at the GIS include Systems Biology, Stem Cell & Developmental Biology, Cancer Biology & Pharmacology, Human Genetics, Infectious Diseases, Genomic Technologies, and Computational & Mathematical Biology. The genomics infrastructure at the GIS is utilized to train new scientific talent, to function as a bridge for academic and industrial research, and to explore scientific questions of high impact. For more information, visit the GIS website: www.gis.a-star.edu.sg.
Forward-looking statements
All statements in this press release that are not historical are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix’ “expectations,” “beliefs,” “hopes,” “intentions,” “strategies,” or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected. These and other risk factors are discussed in Affymetrix’ Form 10-K for the year ended December 31, 2008, and other SEC reports for subsequent quarterly periods.
NOTE: Affymetrix, the Affymetrix logo, Axiom, and GeneTitan are trademarks or registered trademarks of Affymetrix Inc.
4:01PM Affymetrix beats by $0.02, beats on revs (AFFX) 8.21 -0.21 : Reports Q1 (Mar) loss of $0.07 per share, excluding non-recurring items, $0.02 better than the Thomson Reuters consensus of ($0.09); revenues rose 2.0% year/year to $80.2 mln vs the $78.9 mln consensus.
Affymetrix Launches DNA Copy Number Service for Difficult FFPE Samples in Cancer Research
Date : 04/19/2010 @ 6:00AM
Source : Business Wire
Stock : Affymetrix, Inc. (AFFX)
Quote : 8.0 -0.2 (-2.44%) @ 7:22AM
Affymetrix Launches DNA Copy Number Service for Difficult FFPE Samples in Cancer Research
Affymetrix, Inc. (NASDAQ:AFFX) today announced the launch of the Affymetrix® MIP Copy Number Service, designed for cancer researchers using challenging FFPE samples. With the MIP Copy Number Service, scientists can now obtain high-quality allele-specific copy number data from FFPE samples. The service is available for research use only exclusively through the Affymetrix® Research Services Laboratory (ARSL).
DNA obtained from FFPE samples is often of insufficient quantity and too degraded for many array platforms, resulting in low sample pass rates. A recent article in the journal BMC Cancer1 demonstrated that the MIP copy number assay generates high-quality data from ovarian FFPE samples with starting material as low as 75 nanograms (ng) and a sample pass rate greater than 90 percent. In a separate study in the journal Cancer Research2, researchers used MIP technology to distinguish high copy number changes within specific grades of pediatric brain cancer, even with samples stored for more than 20 years.
The Affymetrix MIP Copy Number Service has been successfully used by leading cancer research institutes, including the M. D. Anderson Cancer Center, the University of California, San Francisco, and the Huntsman Cancer Institute at the University of Utah.
"Translational laboratories are having tremendous success using the Affymetrix® MIP 330K Cancer Panel,” said Andy Last, Chief Commercial Officer of Affymetrix. “The broad dynamic range and high resolution of our MIP technology allows the identification of copy number values of 10 and higher, as demonstrated in the journal Cancer Research2,” added Last. “Additionally, in the journal Cancer Genetics and Cytogenetics3, the MIP assay identified both novel copy number aberrations (CNAs) and previously described CNAs in childhood leukemia samples.”
Previous studies have indicated that genomic instability is associated with tumor grade, tumor development, and disease progression. Because the MIP copy number application offers both allele and copy number data on a single platform, researchers now have a more comprehensive tool to evaluate risk factors for the early stages of cancer and disease relapse. Pairing allele information with copy number calls also enables a more in-depth analysis of cancer, including copy-neutral loss of heterozygosity, levels of normal-tumor contamination, and preferential allele amplification.
“Cancer researchers are unlocking the full potential of millions of archived FFPE samples using MIP copy number technology,” said Kevin King, President and CEO of Affymetrix. “Leading cancer researchers can now link copy number data with clinical data from these archived resources. This is the tremendous advantage of the MIP assay and will help researchers yield discoveries that could ultimately improve cancer diagnosis and categorization of patients, and thus lead to more targeted and individualized strategies for the treatment of cancer.”
For more information about the Affymetrix MIP Copy Number Service, please visit www.affymetrix.com/estore/browse/products.jsp?productId=prod150008
1Press J. Z., et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 8:17 (2008).
2Schiffman J. D., et al. Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Research 70(2):512-9 (2010).
3Schiffman J. D., et al. Molecular inversion probes reveal patterns of 9p21 deletion and copy number aberrations in childhood leukemia. Cancer Genetics and Cytogenetics 193(1):9-18 (2009).
About Affymetrix
Affymetrix technology is used by the world’s top pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government and nonprofit research institutes. More than 1,900 systems have been shipped around the world and more than 21,000 peer-reviewed papers have been published using the technology.
Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Cleveland, Ohio, and Singapore. The company has about 1,000 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit www.affymetrix.com.
Forward-looking statements
All statements in this press release that are not historical are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix’ “expectations,” “beliefs,” “hopes,” “intentions,” “strategies,” or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected. These and other risk factors are discussed in Affymetrix’ Form 10-K for the year ended December 31, 2009, and other SEC reports for subsequent quarterly periods.
Affymetrix to Host Conference Call on April 21, 2010 to Announce First Quarter Results
Date : 04/13/2010 @ 4:00PM
Source : Business Wire
Stock : Affymetrix, Inc. (AFFX)
Quote : 7.66 -0.02 (-0.26%) @ 7:22AM
Affymetrix to Host Conference Call on April 21, 2010 to Announce First Quarter Results
Affymetrix, Inc. (NASDAQ: AFFX) today announced that it will release operating results for the first quarter after close of the stock market on Wednesday, April 21, 2010.
The Affymetrix management team will host a conference call on April 21, 2010 at 2:00 PM PT to review its operating results for the first quarter. A live webcast can be accessed by visiting the investor relations section of the company’s website at www.affymetrix.com. In addition, investors and other interested parties can listen by dialing 866-500-AFFX (domestic) or 706-643-2771 (international).
A replay of this call will be available from 5:00 PM PT on April 21, 2010 until 8:00 PM PT on April 28, 2010 at the following numbers: 800-642-1687 (domestic), 706-645-9291 (international). The conference identification number for the replays is 69103813. An archived webcast of the conference call will be available under the investor relations section of the company's website at www.affymetrix.com.
About Affymetrix
Affymetrix technology is used by the world’s top pharmaceutical, diagnostic and biotechnology companies, as well as leading academic, government and not-for-profit research institutes. More than 1,900 systems have been shipped around the world and more than 20,000 peer-reviewed papers have been published using the technology.
Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Cleveland, Ohio, and Singapore. The company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit the company’s website at www.affymetrix.com.
Bookmark With :
sure is nice to see this heading back up. Earning coming up soon, hope for better than expected!
Affymetrix and The Jackson Laboratory Launch First Genotyping Tool for Studying Mouse Strain Diversity
Date : 03/23/2010 @ 9:00AM
Source : Business Wire
Stock : Affymetrix, Inc. (AFFX)
Quote : 7.22 0.0 (0.00%) @ 7:22AM
Affymetrix and The Jackson Laboratory Launch First Genotyping Tool for Studying Mouse Strain Diversity
Affymetrix, Inc. (NASDAQ:AFFX) and The Jackson Laboratory today announced the full commercial launch of the Affymetrix® Mouse Diversity Genotyping Array. This is the first high-density genotyping array that enables researchers to study the complexity of the mouse genome and the diversity among mouse strains.
Because mice and humans share genomes of similar size, content, and organization, mice studies are key elements in the quest to cure human health issues.
The array was developed in the laboratories of Fernando Pardo-Manuel de Villena, PhD, of the University of North Carolina, and Gary Churchill, PhD, of the Center for Genome Dynamics at The Jackson Laboratory. It is manufactured and sold by Affymetrix and is also available as part of a service from The Jackson Laboratory, a world leader in the study of mouse genetics for more than 80 years.
Reporting in the journal Nature Methods1, researchers showed that the Mouse Diversity Genotyping Array is the first that can simultaneously assay 623,124 single nucleotide polymorphisms (SNPs), a 100-fold increase over other currently available arrays, and more than 900,000 invariant genomic regions in the mouse genome. Researchers can use it to genotype virtually any mouse, identify genetic changes involved in disease phenotypes, and genetically monitor important laboratory mouse strains.
“The natural variation between inbred mouse strains provides us with an essential tool to study complex diseases involving the interaction of multiple genes. This is a focal point of biomedical research and drug efficacy testing,” said Jackson Lab Professor Gary Churchill. “Using Affymetrix technology, we have created a way for scientists around the world to analyze these variations with much greater specificity and data reproducibility.”
Through JAX® Services, The Jackson Laboratory offers array hybridization and computational analysis services to researchers worldwide. The JAX® Mouse Diversity Genotyping Array Service is being provided by the same microarray and computational analysis group that participated in the design, validation, and analysis of the Mouse Diversity Genotyping Array. The Jackson Laboratory has run more than 1,000 samples on this array and has developed tools that enable extremely accurate genotype calling.
“Two leading mouse geneticists have identified the most relevant and comprehensive collection of SNPs for studying mouse diversity,” said Kevin King, president and CEO of Affymetrix. “Affymetrix was able to screen these to find the highest performing SNPs, and we believe that together we have produced the best tool for meeting researchers’ needs in this field.”
For more information about the Affymetrix Mouse Diversity Genotyping Array, please visit: www.affymetrix.com/products_services/arrays/specific/mouse_diversity.affx
For more information on JAX® Mouse Diversity Genotyping Array Service, please visit: http://jaxservices.jax.org/mdarray.html
1 Yang, et al. A customized and versatile high-density genotyping array for the mouse. Nature Methods (published online August 9, 2009, doi: 10.1038/nmeth.1359).
About The Jackson Laboratory
The Jackson Laboratory (www.jax.org) is an independent, nonprofit biomedical research institution with more than 1,300 employees in Bar Harbor, Maine, and Sacramento, Calif. Its mission is to discover the genetic basis for preventing, treating and curing human diseases, and to enable research and education for the global biomedical community. Its 38 research groups investigate the genetic basis of cancers, heart disease, osteoporosis, Alzheimer's disease, glaucoma, diabetes and many other human diseases and disorders, as well as normal development, reproduction and aging. The Laboratory is also the world's source for more than 5,000 strains of genetically defined mice, is home of the mouse genome database and is an international hub for scientific courses, conferences, training and education.
The Jackson Laboratory works with over 16,000 laboratories worldwide, providing them with more than 5,000 different strains of mice for the study of diseases including diabetes, cardiovascular disease, cancer, obesity, immune system diseases, ALS, Parkinson’s, Alzheimer’s, hearing loss, blindness and Down syndrome. Research conducted at the Laboratory includes developing mouse models to understand the human variants seen in drug response, such as the genetic basis for type one diabetes.
About Affymetrix
Affymetrix technology is used by the world’s top pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and nonprofit research institutes. More than 1,800 systems have been shipped around the world and more than 20,000 peer-reviewed papers have been published using the technology.
Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Cleveland, Ohio, and Singapore. The company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit the company’s website at www.affymetrix.com.
Forward-looking statements
All statements in this press release that are not historical are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix’ “expectations,” “beliefs,” “hopes,” “intentions,” “strategies” or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected. These and other risk factors are discussed in Affymetrix’ Form 10-K for the year ended December 31, 2008, and other SEC reports for subsequent quarterly periods.
Affymetrix, the Affymetrix logo, and GeneChip® are registered trademarks owned or used by Affymetrix, Inc.
Affymetrix to Webcast Presentations at Two Financial Conferences in March
Date : 03/02/2010 @ 4:00PM
Source : Business Wire
Stock : Affymetrix, Inc. (AFFX)
Quote : 7.55 0.22 (3.00%) @ 7:22AM
Affymetrix to Webcast Presentations at Two Financial Conferences in March
Affymetrix, Inc. (NASDAQ:AFFX) today announced that company management will provide a corporate overview at two upcoming financial conferences.
John Batty, Executive Vice President and CFO, will present at the Cowen and Company 30th Annual Health Care Conference in Boston. A live transmission of the presentation will take place at 4:30 p.m. EST on Tuesday, March 9, 2010. An archived webcast will be available for 30 days.
Mr. Batty will also present at the Barclays Capital Global Healthcare Conference in Miami. A live transmission of the presentation will take place at 11:15 a.m. EST on Tuesday, March 23, 2009. An archived webcast will be available for 30 days.
About Affymetrix Affymetrix technology is used by the world’s top pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and nonprofit research institutes. More than 1,800 systems have been shipped around the world and more than 20,000 peer-reviewed papers have been published using the technology.
Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Cleveland, Ohio, and Singapore. The company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit www.affymetrix.com.
Affymetrix Announces Winner of Anatrace Membrane Protein Award
Date : 02/23/2010 @ 6:28PM
Source : Business Wire
Stock : Affymetrix, Inc. (AFFX)
Quote : 7.52 -0.23 (-2.97%) @ 7:22AM
Affymetrix Announces Winner of Anatrace Membrane Protein Award
Affymetrix, Inc. (Nasdaq: AFFX) today announced that Professor Tom Rapoport of Harvard Medical School and Howard Hughes Medical Institute is the winner of the 2010 Anatrace Membrane Protein Award. The award was presented at the Biophysical Society annual meeting in San Francisco and is sponsored by Anatrace, which is now part of Affymetrix.
The Anatrace Membrane Protein Award recognizes the scientist who has made the most outstanding contribution to understanding the structure or function of membrane proteins. Professor Rapoport’s work has clarified the mechanism by which proteins cross membranes and is the first to determine the structure of a protein-conducting channel.
The Rapoport group has also addressed how incorrectly folded proteins are transported through a membrane for cytosolic degradation, an important process in many diseases, and the mechanism by which the characteristic shape of an organelle is achieved. All of these projects concern fundamental aspects of membrane biology.
Tom Rapoport was elected to the National Academy of Sciences in 2005 and has spent much of his career studying protein translocation and other aspects of membrane biology. His laboratory has published many articles in leading journals, often using Anatrace products from Affymetrix.
“Professor Rapoport’s work clarifying the role of structure in protein function is an important finding as we seek to better understand the onset of disease,” said Kristin Yakimow, senior vice president and general manager of Affymetrix reagents. “Part of our mission is to deliver highly purified reagents to further scientific discovery. We are honored to be able to recognize Professor Rapoport’s work and to be a part of his research.” About Anatrace products Anatrace products from Affymetrix include unique, high-purity detergents and lipids designed to give researchers studying integral membrane proteins the confidence and peace of mind that come from accurate results. Products include lipid-like Fos-Choline® detergents, CYMAL® detergents, and PMAL™ polymeric solubilization aids.
About Affymetrix Affymetrix technology is used by the world’s top pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and not-for-profit research institutes. More than 1,800 systems have been shipped around the world and more than 20,000 peer-reviewed papers have been published using the technology.
Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Cleveland, Ohio, and Singapore. The company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit the company’s website at www.affymetrix.com.
Forward-Looking Statements All statements in this press release that are not historical are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix’ “expectations,” “beliefs,” “hopes,” “intentions,” “strategies,” or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected. These and other risk factors are discussed in Affymetrix’ Form 10-K for the year ended December 31, 2008, and other SEC reports for subsequent quarterly periods.
NOTE: Affymetrix, the Affymetrix logo, and GeneChip® are registered trademarks of Affymetrix Inc. All other trademarks are property of their respective owners.
Affymetrix Reports Fourth Quarter and Fiscal Year 2009 Results
Date : 02/03/2010 @ 4:00PM
Source : Business Wire
Stock : Affymetrix, Inc. (AFFX)
Quote : 5.67 -0.11 (-1.90%) @ 10:51AM
Affymetrix Reports Fourth Quarter and Fiscal Year 2009 Results
Affymetrix, Inc., (NASDAQ: AFFX) today reported its operating results for the fourth quarter and fiscal year ended December 31, 2009. Total revenue for the fourth quarter was $88.8 million, as compared to total revenue of $78.6 million in the fourth quarter of 2008. In constant currency terms, revenue for the fourth quarter 2009 was positively impacted by $2.6 million as compared to 2008. For the full year 2009, total revenue was $327.1 million as compared to $410.2 million, which included a one-time intellectual property payment of $90 million, for 2008
For the fourth quarter of 2009, product revenue was $81.0 million, which consisted of consumable revenue of $71.9 million and instrument revenue of $9.1 million. Service revenue was $5.9 million, and royalties and other revenue were $1.9 million. This compares to fourth quarter 2008 product revenue of $66.6 million, service revenue of $8.5 million, and royalties and other revenue of $3.5 million
For the full year 2009, product revenue was $279.2 million, which consisted of consumable revenue of $255.7 million and instrument revenue of $23.5 million. Service revenue was $39.6 million, and royalties and other revenue were $8.3 million. This compares to full year 2008 product revenue of $270.4 million, service revenue of $32.1 million, and royalties and other revenue of $107.7 million, which included an intellectual property payment of $90 million
Affymetrix shipped 42 systems in the fourth quarter of 2009, bringing its cumulative systems shipped to approximately 1,930
The Company reported a net income of approximately $2.8 million, or $0.04 per diluted share, in the fourth quarter of 2009. This compares to net loss of $318.7 million, or $4.65 per diluted share, in the same period of 2008 which included a pretax goodwill impairment charge of $239.1 million, or $3.49 per diluted share, and a pretax restructuring charge of $14.3 million, or $0.21 per diluted share
Fiscal year 2009 net loss was $23.9 million, or $0.35 per diluted share, which included a $17.4 million gain from the repurchase of convertible notes, or $0.25 per diluted share, and restructuring charges of $2.2 million, or $0.03 per diluted share. This is compared to net loss of $307.9 million, or $4.49 per diluted share, for fiscal year 2008 which included a pretax goodwill impairment charge of $239.1 million, or $3.49 per diluted share, and a pretax restructuring charge of $43.7 million, or $0.64 per diluted share
For the fourth quarter of 2009, cost of product sales was $31.3 million compared to $36.3 million in the same period of 2008. Cost of services and other was $3.7 million compared to $7.0 million in the same period of 2008. Product gross margin was 61.3 percent, as compared to 45.5 percent in the same period of 2008, including the impact of impairment charges of $4.1 million and acquisition-related charges of $0.7 million
For the full year 2009, cost of product sales was $126.4 million as compared to $126.9 million in 2008. Cost of services and other was $23.9 million compared to $25.2 million in 2008. Product gross margin was 54.7 percent as compared to 53.1 percent in 2008
For the fourth quarter of 2009, operating expenses were $51.3 million as compared to operating expenses of $313.5 million, which included $239.1 million and $3.6 million of goodwill and other asset impairment charges, respectively, and restructuring charges of $14.3 million, in the fourth quarter of 2008
For the full year 2009, operating expenses were $209.9 million which included restructuring charges of $2.2 million, as compared to operating expenses of $500.6 million, which included goodwill impairment charges of $239.1 million and restructuring charges of $43.7 million, in 2008
“In 2009, we successfully executed against the business priorities that we described at the outset of the year, specifically reengineering our technology platform, entering new markets and increasing our operating leverage,” stated President and CEO, Kevin King. “Revenue for the fourth quarter increased 13% over the prior year, driven by an 8% increase in our RNA business and a 30% increase in sales of our genotyping products. In 2010, we expect to generate improved revenue growth and to be profitable for the year.” Quarterly Highlights Genotyping In October, Kaiser Permanente and the University of California, San Francisco (UCSF) entered into an agreement with Affymetrix to conduct genome-wide analyses of DNA samples from 100,000 Kaiser Permanente members for a large-scale research program designed to create a new resource for studying disease, health, and aging. Scientists from the program will use the just-launched Axiom Genotyping Solution™, which delivers high-throughput, automated technology enabling researchers to find novel and common genetic variations associated with complex disease
Additionally, the Company announced that the Institute for Pharmacogenomics and Individualized Therapy (IPIT) at the University of North Carolina in Chapel Hill is using Affymetrix’s DMET™ Plus biomarker panel to expand the Pharmacogenetics for Every Nation Initiative (PGENI). The PGENI’s mission is to help developing countries use genetic information to improve their drug dosing decision-making process
Affymetrix' management team will host a conference call on February 3, 2010 at 2:00 p.m. PT to review its operating results for the fourth quarter and fiscal year 2009. A live webcast can be accessed by visiting the Investor Relations section of the Company’s website at www.affymetrix.com. In addition, investors and other interested parties can listen by dialing domestic: (866) 500-AFFX, international: (706) 643-2771
A replay of this call will be available from 5:00 p.m. PT on February 3, 2010 until 8:00 p.m. PT on February 10, 2010 at the following numbers: domestic: (800) 642-1687, international: (706) 645-9291. The passcode for both replays is 50159245. An archived webcast of the conference call will be available under the Investor Relations section of the Company's website at www.affymetrix.com
About Affymetrix GeneChip® microarray technology is the industry-standard tool for analyzing complex genetic information. After inventing the technology in the late 1980s, Affymetrix scientists have been dedicated to developing innovative products that provide researchers with a more complete view of the genome. These products accelerate genetic research that will allow physicians to develop diagnostics and tailor treatments for individual patients by identifying and measuring the genetic information associated with complex diseases. Today, Affymetrix technology is used by the world's top pharmaceutical, diagnostic, and biotechnology companies, as well as by leading academic, government, and non-profit organizations. Affymetrix has installed almost 1,950 systems around the world and more than 21,000 peer-reviewed papers have been published using its microarray technology. Affymetrix is headquartered in Santa Clara, California. For more information about Affymetrix, please visit the company's website at www.affymetrix.com
All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies" or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to: risk relating to the company’s ability to successfully commercialize new products, risk relating to past and future acquisitions, including the ability of the company to successfully integrate such acquisitions into its existing business; risks of the company's ability to achieve and sustain higher levels of revenue, higher gross margins and reduced operating expenses; uncertainties relating to technological approaches, risks associated with manufacturing and product development; personnel retention; uncertainties relating to cost and pricing of Affymetrix products; dependence on collaborative partners; uncertainties relating to sole-source suppliers; uncertainties relating to FDA and other regulatory approvals; competition; risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix' Form 10-K for the year ended December 31, 2008, and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based
PLEASE NOTE: Affymetrix, the Affymetrix logo, GeneChip, and all other trademarks are the property of Affymetrix, Inc
AFFYMETRIX, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (IN THOUSANDS) (UNAUDITED) December 31, December 31, 2009 2008 ASSETS: (Note 1) Current assets: Cash and cash equivalents $ 65,642 $ 113,292 Restricted cash—short-term portion 1,686 4,402 Available-for-sale securities—short-term portion 213,377 250,970 Accounts receivable, net 64,933 62,726 Inventories 54,490 51,333 Deferred tax assets—current portion 1,172 1,077 Prepaid expenses and other current assets 15,903 15,725 Total current assets 417,203 499,525 Available-for-sale securities—long-term portion 64,760 26,900 Property and equipment, net 68,182 89,345 Acquired technology rights, net 49,855 62,569 Deferred tax assets—long-term portion 4,720 4,764 Restricted cash—long-term portion 1,109 2,175 Other assets 25,121 28,032 Total assets $ 630,950 $ 713,310 LIABILITIES AND STOCKHOLDERS’ EQUITY: Current liabilities: Accounts payable and accrued liabilities $ 57,183 $ 62,559 Deferred revenue—current portion 14,534 16,198 Total current liabilities 71,717 78,757 Deferred revenue—long-term portion 3,898 3,583 Other long-term liabilities 10,295 10,972 Convertible notes 247,201 316,341 Stockholders’ equity: Common stock 710 703 Additional paid-in capital 733,378 721,641 Accumulated other comprehensive income (loss) 4,051 (2,296 ) Accumulated deficit (440,300 ) (416,391 ) Total stockholders’ equity 297,839 303,657 Total liabilities and stockholders’ equity $ 630,950 $ 713,310 Note 1: The condensed consolidated balance sheet at December 31, 2008 has been derived from the audited consolidated financial statements at that date included in the Company’s Form 10-K for the fiscal year ended December 31, 2008
AFFYMETRIX, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (IN THOUSANDS, EXCEPT PER SHARE AMOUNTS) (UNAUDITED) Three Months Ended Twelve Months Ended December 31, December 31, 2009 2008 2009 2008 REVENUE: Product sales $ 80,988 $ 66,612 $ 279,186 $ 270,392 Services 5,885 8,539 39,563 32,096 Royalties and other revenue 1,915 3,423 8,345 107,761 Total revenue 88,788 78,574 327,094 410,249 COSTS AND EXPENSES: Cost of product sales 31,330 36,328 126,377 126,909 Cost of services and other 3,650 6,990 23,949 25,231 Research and development 16,950 25,384 77,358 84,482 Selling, general and administrative 34,562 34,379 130,838 127,161 Acquired in-process technology - 300 - 6,200 Restructuring charges 283 14,328 2,180 43,707 Goodwill impairment (credits) charges (450 ) 239,098 (450 ) 239,098 Total costs and expenses 86,325 356,807 360,252 652,788 Income (loss) from operations 2,463 (278,233 ) (33,158 ) (242,539 ) Interest income and other, net 1,299 3,799 2,589 14,629 Interest expense 2,435 3,457 10,945 14,091 Gain from repurchase of convertible notes - - 17,447 - Income (loss) before income taxes 1,327 (277,891 ) (24,067 ) (242,001 ) Income tax (benefit) provision (1,468 ) 40,825 (158 ) 65,918 Net income (loss) $ 2,795 $ (318,716 ) $ (23,909 ) $ (307,919 ) Basic and diluted net income (loss) per common share $ 0.04 $ (4.65 ) $ (0.35 ) $ (4.49 ) Shares used in computing basic net income (loss) per common share 68,820 68,598 68,722 68,556 Shares used in computing diluted net income (loss) per common share 69,374 68,598 68,722 68,556
Affymetrix to Host Conference Call on February 3, 2010 to Announce Fourth Quarter and Fiscal 2009 Results
Date : 01/20/2010 @ 6:00AM
Source : Business Wire
Stock : Affymetrix, Inc. (AFFX)
Quote : 6.42 0.15 (2.39%) @ 7:40PM
Affymetrix to Host Conference Call on February 3, 2010 to Announce Fourth Quarter and Fiscal 2009 Results
Affymetrix, Inc. (Nasdaq: AFFX) today announced that it will release operating results for the fourth quarter and fiscal year 2009 after close of the stock market on Wednesday, February 3, 2010
Affymetrix' management team will host a conference call on February 3, 2010 at 2:00 P.M. PT to review its operating results. A live webcast can be accessed by visiting the Investor Relations section of www.affymetrix.com. Investors and other interested parties can also listen by dialing 866-500-AFFX (domestic) or 706-643-2771 (international)
A replay of this call will be available from 5:00 P.M. PT on February 3, 2010 until 8:00 P.M. PT on February 10, 2010, at 800-642-1687 (domestic) or 706-645-9291 (international). The conference identification number for the replays is 50159245. An archived webcast of the conference call will be available under the Investor Relations section of www.affymetrix.com
About Affymetrix Affymetrix technology is used by the world’s top pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government and not-for-profit research institutes. More than 1,800 systems have been shipped around the world and more than 20,000 peer-reviewed papers have been published using the technology
Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Cleveland, Ohio, and Singapore. The company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit the company’s website at www.affymetrix.com
Affymetrix AFFX Barclays Capital drops from Equal Weight to Underweight $6 to $3
Luminex Posts Loss
By Zacks Equity Research
On 10:14 am EST, Monday November 30, 2009
Technologies CorporationLuminex Corporation
AFFX 4.91 +0.14
LIFE 50.50 +0.25
LMNX 14.56 +0.28
SQNM 4.30 +0.08
Luminex Corporation (NasdaqGM: LMNX - News) reported a third-quarter loss of $0.6 million or 1 cent per share as opposed to a net income of $3.2 million or 8 cents in the comparable period of 2008. The Zacks Consensus Estimate for the reported quarter was a gain of 7 cents. The loss in the quarter was attributable to the higher operating expenses which more than offset the increase in revenues.
Total revenues for the reported quarter came in at $29.1 million as against $28.9 million in the year-ago period, up 1%. As per segments, revenues from the Technology segment came in at 22 million as against $22.6 million in the year-ago quarter. Assay group sales for the quarter came in at approximately $7.1 million, up 12% over the comparable quarter of 2008. Total assay sales by Luminex and its partners for the reported quarter came in at $80.8 million, up 16% from the third quarter of 2008.
The company shipped a record 259 systems in the quarter including 11 of the new FlexMAP 3D instruments. Cumulative systems shipments stood at 6,514 at the end of the quarter, up 15% from a year ago.
Operating expenses for the quarter came in at $19.3 million as against $16.6 million in the year-ago quarter. Research and development spend was $5.6 million, up 27%. Selling, general and administrative expenses came in at $ 13.7 million, up 12%. The increase was attributable to additional personnel cost and related stock compensation travel cost associated with an increase in the number of employees, which increased from 381 to 423 in the reported quarter.
The company exited the quarter with cash and investments of $115 million as against $124.4 million at the end of 2008. Luminex has narrowed the full year revenue forecast to $118 – $126 million from $118 – $132 million.
Luminex Corporation, founded in 1995 and based in Austin, Texas, develops, manufactures and markets proprietary biological testing technologies with applications throughout the life sciences industry. It competes with players such as Life Technologies Corporation (NasdaqGS: LIFE - News), Affymetrix Inc. (NasdaqGS: AFFX - News) and Sequenom Inc. (NasdaqGM: SQNM - News) in the industry.
Affymetrix Announces Major Genotyping Project With Kaiser Permanente and the University of California at San Francisco for NIH-Funded Epidemiology Study
100,000-Sample Study to Be Performed Using New Axiom™ Genotyping Solution
Press Release
Source: Affymetrix, Inc.
On 9:05 am EDT, Wednesday October 14, 2009
Companies:Affymetrix Inc.
SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix, Inc. (Nasdaq:AFFX - News) today announced that the Kaiser Permanente Research Program on Genes, Environment, and Health (RPGEH) and the University of California at San Francisco (UCSF) have entered into an agreement with Affymetrix to support genome-wide analyses of DNA samples from 100,000 Kaiser Permanente members.
The members have volunteered for a large-scale research program designed to create a new resource for studying disease, health, and aging. Scientists from the program will use the just-launched Axiom Genotyping Solution, which delivers high-throughput, automated technology and enables researchers to find novel and common genetic variations associated with complex disease.
DNA studies will be linked to Kaiser Permanente’s electronic health record system, the largest of its kind. Information from health surveys and environmental data will also be analyzed. These resources will give researchers an entirely new platform for studying genetic and environmental influences over time on a wide variety of health conditions, across diverse populations.
The program is being funded by a $24.8 million grant from the National Institutes of Health (NIH)1, and over the next two years, a significant portion of this amount is expected to be used to purchase the Axiom Genotyping Solution.
The Kaiser Permanente RPGEH is a growing resource for scientific research designed to facilitate epidemiologic studies of both genetic and environmental influences on common health conditions, such as heart disease, diabetes, cancer, asthma, mental health disorders, and many others.
“The NIH grant gives Kaiser Permanente and UCSF an opportunity to utilize a new model for studying human genetics,” said Kevin King, president and CEO of Affymetrix. “We greatly value the relationship we have built with the program leaders over the last two years, and we are excited that our technology will be used to help researchers study effective prevention and treatment strategies to improve healthcare and quality of life.”
The Axiom Solution is configured to continually validate and incorporate the output of large-scale sequencing projects. Initial offerings are designed from public databases of human variations and cover historical HapMap data supplemented by subsequent releases of additional variants. In addition, Affymetrix is screening millions of putative SNPs and insertions/deletions that are being discovered by the 1000 Genomes Project and other sources, and will make these available to researchers using the Axiom Solution.
The solution consists of Axiom Array Plates, complete Axiom Reagent Kits, an automated target preparation station developed jointly by Affymetrix and Beckman Coulter, plus the GeneTitan™ Multi-Channel (MC) Instrument. The GeneTitan MC Instrument integrates a hybridization oven, fluidics processing, CCD imaging device, and analysis software for maximum data reproducibility, user productivity, and scalability.
For more information on the Axiom Genotyping Solution, please visit www.axiom.affymetrix.com.
1Kaiser Permanente and UCSF joint press release:
http://xnet.kp.org/newscenter/pressreleases/ncal/2009/101209rpgehanducsfgrant.html
Affymetrix and Beckman Coulter Join Forces to Provide Robust, Automated Target Preparation Solutions
Press Release
Source: Affymetrix, Inc.
On Wednesday August 26, 2009, 9:00 am EDT
Companies:Affymetrix Inc.
SANTA CLARA, Calif. & ORANGE COUNTY, Calif.--(BUSINESS WIRE)--Affymetrix, Inc. (Nasdaq: AFFX - News) and Beckman Coulter, Inc. today announced that they have entered into an agreement to offer researchers co-developed products from the market leaders in microarrays and automated liquid handlers. The collaboration will provide scientists with optimized, robust solutions for genomic research, fortified by end-to-end support.
The partnership will yield an expanding list of Affymetrix-validated automated target preparation methods, developed on an Affymetrix-specific configuration of Beckman Coulter’s precise and reliable Biomek FXp Dual Arm Multichannel–Span 8 Liquid Handler. This platform will provide researchers with standardized systems that include all components necessary to run Affymetrix genotyping and gene expression assays.
Major benefits of the solution will include the flexibility to process samples using Affymetrix GeneChip® Arrays or Array Plates with a single method, user-friendly interfaces, rapid implementation of new methods, a validated platform, elimination of costly mistakes and delivery of high-quality results.
“Beckman Coulter’s long history in manufacturing quality automation platforms with proven reliability make the company the ideal partner for developing automated target prep assays,” said Kevin King, president and CEO of Affymetrix. “These products not only provide a much needed target prep solution for our large installed base of GeneChip Array cartridge users, but very importantly, this agreement aligns with our strategic goals to reengineer the Affymetrix platform. With automated target prep robotics in front of our GeneTitan™ System, our customers will benefit from walk-away automation from prepared samples all the way through array processing and data generation.”
“We chose to work with Affymetrix because their genomics expertise and technologies are a great match for Beckman Coulter’s automation solutions,” said Wing Pang, corporate vice president of discovery products at Beckman Coulter. “Customers will soon see the fruits of this collaboration with the availability of automated target prep solutions for microarrays that address a wide range of sophisticated genetic analysis assays.”
Automated target preparation solutions from Affymetrix and Beckman Coulter are for research use only and are not for use in diagnostic procedures.
The Biomek FXp Dual Arm Multichannel–Span 8 Liquid Handler is for laboratory use only and not for use in diagnostic procedures.
NOTE: Affymetrix, the Affymetrix logo and GeneChip® are registered trademarks owned or used by Affymetrix Inc.
Beckman Coulter, the stylized logo and Biomek are registered trademarks of Beckman Coulter, Inc.
In North America please send reader inquiries regarding Beckman Coulter directly to c/o K. Delgado, Harte Hanks, 1753 South Pointe Avenue, Ontario, CA 91761. Or e-mail to k_delgado@harte-hanks.com.
For European reader inquiries, please contact: Manuela Jeremaes, Marketing Communications Manager, Beckman Coulter Eurocenter, PO Box 303, 1260 Nyon, Switzerland. Or email: mjeremaes@beckman.com.
Affymetrix AFFX Piper Jaffray Upgraded from Neutral to Overweight
Affymetrix Q2 2009 Earnings Transcript
http://seekingalpha.com/article/150641-affymetrix-q2-2009-earnings-transcript?source=yahoo
Affymetrix shares surge on 2Q profit
Affymetrix shares jump on report of 2nd-quarter profit following gain from debt buyback
On Thursday July 23, 2009, 11:29 am EDT
Companies:Affymetrix inc.
NEW YORK (AP) -- Shares of Affymetrix Inc., which makes genetic data analysis instruments, jumped Thursday after the company said it swung to a second-quarter profit on a debt buyback.
The stock gained $1.73, or 29.4 percent, to reach $7.61 in midday trading. Shares have traded between $1.78 and $10.99 over the last 52 weeks.
Late Wednesday, the Santa Clara, Calif.-based company said it earned $7.3 million, or 11 cents per share, compared with a loss of $3.6 million, or 5 cents per share, during the same period a year prior. Revenue fell 6 percent to $81.6 million from $86.9 million.
Analysts surveyed by Thomson Reuters expected profit of 5 cents per share on revenue of $92.2 million.
The company said it had a $17.4 million, or 25 cents per share, gain during the quarter from a debt repurchase related to a convertible notes buyback.
This stock used to trade for $200...now almost $2 Won't be here long. No Brainer at these prices
This board needs someone to post their resume
here.
From a technical standpoint we are close, but
not quite there. A nice hammeer would help
immensely on the chart pattern.
This stock is really beat down, trading at
cash value more or less. Any opinions.
Followers
|
4
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
105
|
Created
|
11/13/07
|
Type
|
Free
|
Moderators |
http://www.affymetrix.com/index.affx
http://finance.yahoo.com/q/ks?s=AFFX
Affymetrix, Inc. engages in the development, manufacture, sale, and servicing of consumables and systems for genetic analysis for use in the life sciences and clinical healthcare markets. It offers GeneChip system and related microarray technology platform for acquiring, analyzing, and managing genetic information. The company's GeneChip microarray platform includes disposable DNA probe arrays containing genetic information on a chip; reagents for extracting, amplifying, and labeling target nucleic acids; a fluidics station for introducing the test sample to the probe arrays; a hybridization oven for optimizing the binding of samples to the probe arrays; a scanner to read the fluorescent image from the probe arrays; and software to analyze and manage the resulting genetic information. It also offers related microarray technology that includes instrumentation, software, and licenses for fabricating, scanning, collecting, and analyzing results from low density microarrays. In addition, the company markets CustomExpress, CustomSeq, and NimbleExpress products that enable its customers to design their own custom GeneChip expression arrays or sequence arrays for organisms of interest to them. Affymetrix sells its products directly to pharmaceutical, biotechnology, agrichemical, diagnostics, industrial, and consumer products companies, as well as to academic research centers, government research laboratories, private foundation laboratories, and clinical reference laboratories in North America and Europe. The company also offers its products in Latin America, India, the Middle East, and Asia Pacific regions, including China through distributors. It has collaboration agreements with Qiagen, GmbH; PreAnalytiX GmbH; Perlegen Sciences, Inc.; bioM?rieux, Inc.; F. Hoffmann-La Roche Ltd.; Veridex, LLC.; Sysmex Corporation; Caliper Life Sciences, Inc.; Caliper Life Sciences, Inc.; and IPSOGEN. The company was founded in 1991 and is headquartered in Santa Clara, California.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |